View Financial HealthSYN-TECH Chem. & Pharm 배당 및 자사주 매입배당 기준 점검 5/6SYN-TECH Chem. & Pharm 수익으로 충분히 충당되는 현재 수익률 5.54% 보유한 배당금 지급 회사입니다. 다음 지급일은 13th August, 2026 이며 배당락일은 다음과 같습니다. 16th July, 2026.핵심 정보5.5%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률3.4%다음 배당 지급일13 Aug 26배당락일16 Jul 26주당 배당금n/a배당 성향69%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jul 09Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 16 July 2026. Payment date: 13 August 2026. Payout ratio is a comfortable 69% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (2.9%).Declared Dividend • Jun 10Dividend reduced to NT$4.00Dividend of NT$4.00 is 25% lower than last year. Ex-date: 16th July 2026 Payment date: 13th August 2026 Dividend yield will be 5.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (69% earnings payout ratio) and cash flows (41% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 23% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.0% EPS decline seen over the last 5 years.Upcoming Dividend • Jul 14Upcoming dividend of NT$5.30 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 15 August 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.6%).Declared Dividend • Jun 11Dividend increased to NT$5.30Dividend of NT$5.30 is 51% higher than last year. Ex-date: 21st July 2025 Payment date: 15th August 2025 Dividend yield will be 6.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.9% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Upcoming Dividend • Jul 12Upcoming dividend of NT$3.50 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 57% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.0%).Declared Dividend • Jun 22Dividend increased to NT$3.50Dividend of NT$3.50 is 17% higher than last year. Ex-date: 19th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (57% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 1.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.모든 업데이트 보기Recent updatesUpcoming Dividend • Jul 09Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 16 July 2026. Payment date: 13 August 2026. Payout ratio is a comfortable 69% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (2.9%).New Risk • Jun 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.16b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.16b market cap, or US$99.2m).Declared Dividend • Jun 10Dividend reduced to NT$4.00Dividend of NT$4.00 is 25% lower than last year. Ex-date: 16th July 2026 Payment date: 13th August 2026 Dividend yield will be 5.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (69% earnings payout ratio) and cash flows (41% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 23% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.0% EPS decline seen over the last 5 years.Reported Earnings • May 11First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.70 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00 (down from NT$1.70 in 1Q 2025). Revenue: NT$275.6m (down 13% from 1Q 2025). Net income: NT$71.7m (down 5.4% from 1Q 2025). Profit margin: 26% (up from 24% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.New Risk • Mar 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (91% payout ratio). Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.13b market cap, or US$99.1m).Reported Earnings • Feb 28Full year 2025 earnings released: EPS: NT$5.87 (vs NT$8.82 in FY 2024)Full year 2025 results: EPS: NT$5.87 (down from NT$8.82 in FY 2024). Revenue: NT$1.30b (up 3.4% from FY 2024). Net income: NT$261.6m (down 34% from FY 2024). Profit margin: 20% (down from 31% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.공고 • Feb 24SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026. Location: no,168, k`ai yuan rd., sinying district, tainan city TaiwanReported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$1.73 (vs NT$2.60 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.73 (down from NT$2.60 in 3Q 2024). Revenue: NT$336.7m (up 1.9% from 3Q 2024). Net income: NT$77.4m (down 33% from 3Q 2024). Profit margin: 23% (down from 35% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Aug 07Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$2.21 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$2.21 in 2Q 2024). Revenue: NT$324.8m (down 5.3% from 2Q 2024). Net income: NT$16.6m (down 83% from 2Q 2024). Profit margin: 5.1% (down from 29% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year.Upcoming Dividend • Jul 14Upcoming dividend of NT$5.30 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 15 August 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.6%).Declared Dividend • Jun 11Dividend increased to NT$5.30Dividend of NT$5.30 is 51% higher than last year. Ex-date: 21st July 2025 Payment date: 15th August 2025 Dividend yield will be 6.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.9% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 09First quarter 2025 earnings released: EPS: NT$1.70 (vs NT$1.96 in 1Q 2024)First quarter 2025 results: EPS: NT$1.70 (down from NT$1.96 in 1Q 2024). Revenue: NT$315.8m (up 17% from 1Q 2024). Net income: NT$75.8m (down 13% from 1Q 2024). Profit margin: 24% (down from 32% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year and the company’s share price has also increased by 12% per year.공고 • Apr 30SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2025 Results on May 07, 2025SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2025 results on May 07, 2025Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$83.00, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 38% over the past three years.Reported Earnings • Mar 09Full year 2024 earnings released: EPS: NT$8.82 (vs NT$5.63 in FY 2023)Full year 2024 results: EPS: NT$8.82 (up from NT$5.63 in FY 2023). Revenue: NT$1.26b (up 13% from FY 2023). Net income: NT$393.3m (up 57% from FY 2023). Profit margin: 31% (up from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 16% per year.공고 • Feb 25SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwan공고 • Feb 15SYN-TECH Chem. & Pharm. Co., Ltd. to Report Fiscal Year 2024 Results on Feb 24, 2025SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report fiscal year 2024 results on Feb 24, 2025New Risk • Nov 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • Nov 18Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: NT$330.6m (flat on 3Q 2023). Net income: NT$116.0m (up 26% from 3Q 2023). Profit margin: 35% (up from 28% in 3Q 2023).공고 • Oct 26SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q3, 2024 Results on Nov 04, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q3, 2024 results on Nov 04, 2024Reported Earnings • Aug 13Second quarter 2024 earnings released: EPS: NT$2.21 (vs NT$1.52 in 2Q 2023)Second quarter 2024 results: EPS: NT$2.21 (up from NT$1.52 in 2Q 2023). Revenue: NT$343.0m (up 40% from 2Q 2023). Net income: NT$98.6m (up 46% from 2Q 2023). Profit margin: 29% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.공고 • Jul 27SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q2, 2024 Results on Aug 05, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q2, 2024 results on Aug 05, 2024Upcoming Dividend • Jul 12Upcoming dividend of NT$3.50 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 57% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.0%).Buy Or Sell Opportunity • Jul 08Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 18% to NT$98.20. The fair value is estimated to be NT$79.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.4% over the last 3 years. Earnings per share has grown by 3.9%.Declared Dividend • Jun 22Dividend increased to NT$3.50Dividend of NT$3.50 is 17% higher than last year. Ex-date: 19th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (57% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 1.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$1.96 (vs NT$1.47 in 1Q 2023)First quarter 2024 results: EPS: NT$1.96 (up from NT$1.47 in 1Q 2023). Revenue: NT$269.8m (flat on 1Q 2023). Net income: NT$87.4m (up 33% from 1Q 2023). Profit margin: 32% (up from 25% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 2% per year.공고 • Apr 28SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2024 Results on May 06, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2024 results on May 06, 2024Buy Or Sell Opportunity • Apr 23Now 20% overvaluedOver the last 90 days, the stock has fallen 2.5% to NT$82.30. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 2.5%.Buy Or Sell Opportunity • Mar 01Now 20% overvaluedOver the last 90 days, the stock has fallen 5.5% to NT$82.40. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 2.7%.공고 • Feb 27SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024. Location: No.168, Kai Yuan Rd., Hsin-Ying District Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider 2023 Audit Committee's Review Report; to consider 2023 Employees and Directors' Compensation Information; to consider Status of 2023 Cash Dividend Distribution; to consider 2023 Directors' Remuneration Information; to consider 2023 Business Report and Financial Statements; to consider distribution plan of 2023 earnings; and to consider other matters.Reported Earnings • Nov 08Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: NT$2.07 (down from NT$2.54 in 3Q 2022). Revenue: NT$330.4m (up 17% from 3Q 2022). Net income: NT$92.5m (down 18% from 3Q 2022). Profit margin: 28% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Aug 08Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: EPS: NT$1.51 (down from NT$3.11 in 2Q 2022). Revenue: NT$245.1m (down 17% from 2Q 2022). Net income: NT$67.5m (down 46% from 2Q 2022). Profit margin: 28% (down from 42% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) exceeded analyst estimates by 18%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.Upcoming Dividend • Jul 14Upcoming dividend of NT$3.00 per share at 3.5% yieldEligible shareholders must have bought the stock before 21 July 2023. Payment date: 18 August 2023. Payout ratio is a comfortable 44% but the company is not cash flow positive. Trailing yield: 3.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (1.7%).Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: NT$6.62 (up from NT$3.38 in FY 2021). Revenue: NT$986.3m (up 32% from FY 2021). Net income: NT$295.3m (up 184% from FY 2021). Profit margin: 30% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) missed analyst estimates by 4.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.공고 • Dec 30SYN-TECH Chem. & Pharm. Co., Ltd. Announces Appointment of Corporate Governance OfficerSYN-TECH Chem. & Pharm. Co., Ltd. announced appointment of Corporate Governance Officer. Name, title, and resume of the previous position holder: N/A. Name, title, and resume of the new position holder: Maggie Juang /financial & accounting officer of Syn-Tech. Effective date: December 29, 2022.Price Target Changed • Nov 16Price target decreased to NT$80.00Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$76.40. Stock is up 9.1% over the past year. The company is forecast to post earnings per share of NT$3.02 for next year compared to NT$3.38 last year.Reported Earnings • Nov 06Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: NT$2.54 (up from NT$0.94 in 3Q 2021). Revenue: NT$281.8m (up 77% from 3Q 2021). Net income: NT$113.3m (up 302% from 3Q 2021). Profit margin: 40% (up from 18% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 37%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 07Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: NT$1.72 (up from NT$0.74 in 2Q 2021). Revenue: NT$209.1m (down 3.3% from 2Q 2021). Net income: NT$68.8m (up 209% from 2Q 2021). Profit margin: 33% (up from 10% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 192%. Over the next year, revenue is forecast to grow 32%, compared to a 39% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.공고 • Aug 03SYN-TECH Chem. & Pharm. Co., Ltd. Announces Executive ChangesSYN-TECH Chem. & Pharm. Co., Ltd. announced that Chun-Cheng, Hung/synthesis department manager of SCP, has replaced Chun-Tzer, Tsai/director of Syn-Tech, as Research and development officer. Syn-Tech has announced the change of research and development officer on July 1, 2022. The case was approved by the board of Syn-Tech on August 1, 2022.Upcoming Dividend • Jul 14Upcoming dividend of NT$1.93 per shareEligible shareholders must have bought the stock before 21 July 2022. Payment date: 19 August 2022. Payout ratio is a comfortable 75% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (6.8%). In line with average of industry peers (2.8%).공고 • Jul 03SYN-TECH Chem. & Pharm. Co., Ltd. Announces Change of Research and Development OfficerSYN-TECH Chem. & Pharm. Co., Ltd. announced change of research and development officer. Name, title, and resume of the previous position holder: Chun-Tzer, Tsai/director of Syn-Tech. Name, title, and resume of the new position holder: Chun-Cheng, Hung/synthesis department manager of SCP. Effective date is July 1, 2022.공고 • Jun 22SYN-TECH Chem. & Pharm. Co., Ltd. Announces Cash Dividend, Payable on August 19, 2022SYN-TECH Chem. & Pharm. Co., Ltd. announced cash dividend of TWD 86,128,033 (TWD 2.15 per share). Ex-rights (Ex-dividend) date is July 21, 2022. Ex-rights (Ex-dividend) record date is July 27, 2022. Payment date of cash dividend distribution is August 19, 2022.Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: NT$0.85 (down from NT$1.73 in 1Q 2021). Revenue: NT$159.5m (down 32% from 1Q 2021). Net income: NT$34.2m (down 34% from 1Q 2021). Profit margin: 22% (in line with 1Q 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 73%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Price Target Changed • Apr 27Price target decreased to NT$66.00Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$65.30. Stock is down 35% over the past year. The company is forecast to post earnings per share of NT$2.47 for next year compared to NT$3.38 last year.Reported Earnings • Mar 12Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: NT$3.38 (down from NT$6.21 in FY 2020). Revenue: NT$746.6m (down 24% from FY 2020). Net income: NT$103.8m (down 44% from FY 2020). Profit margin: 14% (down from 19% in FY 2020). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Over the next year, revenue is expected to shrink by 9.3% compared to a 20% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 5% per year.Reported Earnings • Nov 10Third quarter 2021 earnings released: EPS NT$0.94 (vs NT$1.14 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: NT$159.2m (down 28% from 3Q 2020). Net income: NT$28.2m (down 18% from 3Q 2020). Profit margin: 18% (up from 16% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 09Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 16 September 2021. Payment date: 07 October 2021. Trailing yield: 5.5%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.3%).Reported Earnings • Aug 06Second quarter 2021 earnings released: EPS NT$0.74 (vs NT$2.35 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$216.3m (down 29% from 2Q 2020). Net income: NT$22.2m (down 69% from 2Q 2020). Profit margin: 10% (down from 23% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • May 06First quarter 2021 earnings released: EPS NT$1.73 (vs NT$1.56 in 1Q 2020)The company reported a solid first quarter result with improved earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: NT$235.6m (flat on 1Q 2020). Net income: NT$52.0m (up 11% from 1Q 2020). Profit margin: 22% (up from 20% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to NT$95.60, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 35% over the past three years.분석 기사 • Mar 19SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공고 • Mar 18SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million.SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million on March 16, 2021. The transaction will be settled by exchange of 4.5 million shares of SYN-TECH of NTD 75.24 per share. If there is insufficient exchange for one share, SYN-TECH shall, within 30 days after completing amendment registration, pay the difference between assessed business value and the share value in cash to SCP at once. The deal is subject to Standard Chemical obtaining approval from shareholders and is expected to close on October 1, 2021.Reported Earnings • Mar 18Full year 2020 earnings released: EPS NT$6.21 (vs NT$5.31 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$983.8m (up 3.9% from FY 2019). Net income: NT$186.7m (up 17% from FY 2019). Profit margin: 19% (up from 17% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.공고 • Mar 17SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021, at 14:00 Taipei Standard Time. Location: No.168, Kai Yuan Rd., Hsin-Ying District, Tainan City Taiwan Agenda: To consider 2020 Business Report; to consider Supervisors' Review Report on 2020 Financial Statements; to consider 2020 Employees' Compensation and Directors & Supervisors' Compensation Information; to consider Syn-Tech will transfer the API synthesis department that spinning-off from S.C.P, and issue new shares; to consider 2020 Business Report and Financial Statements; to consider the proposed distribution plan for year 2020 earnings; to consider the amendment to the Articles of Incorporation; to consider the amendment to the Procedures for Election of Directors and Supervisors; to consider the amendment to the Regulations Governing the Acquisition and Disposal of Assets; to consider the amendment to the Regulations Governing Loaning of Funds; and to consider other matters.Is New 90 Day High Low • Feb 27New 90-day high: NT$82.50The company is up 9.0% from its price of NT$75.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period.분석 기사 • Feb 26Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend YieldIs SYN-TECH Chem. & Pharm. Co., Ltd. ( GTSM:1777 ) a good dividend stock? How can we tell? Dividend paying companies...분석 기사 • Feb 05Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?SYN-TECH Chem. & Pharm (GTSM:1777) has had a rough month with its share price down 1.2%. However, stock prices are...분석 기사 • Jan 10SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their SharesIdeally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...Is New 90 Day High Low • Dec 21New 90-day high: NT$77.30The company is up 2.0% from its price of NT$75.50 on 23 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period.분석 기사 • Dec 19SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather SparinglySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Nov 28Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend YieldIs SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) a good dividend stock? How can we tell? Dividend paying companies...Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS NT$1.14The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$220.3m (down 20% from 3Q 2019). Net income: NT$34.3m (down 39% from 3Q 2019). Profit margin: 16% (down from 21% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 13New 90-day low: NT$73.70The company is down 16% from its price of NT$88.00 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: NT$75.60The company is down 16% from its price of NT$89.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 1777 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: 1777 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장SYN-TECH Chem. & Pharm 배당 수익률 vs 시장1777의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (1777)5.5%시장 하위 25% (TW)1.6%시장 상위 25% (TW)5.2%업계 평균 (Pharmaceuticals)3.2%분석가 예측 (1777) (최대 3년)n/a주목할만한 배당금: 1777 의 배당금( 5.54% )은 TW 시장에서 배당금 지급자의 하위 25%( 1.64% )보다 높습니다.고배당: 1777 의 배당금( 5.54% )은 TW 시장( 5.18% )주주 대상 이익 배당수익 보장: 합리적인 지급 비율 ( 69.3% )을 통해 1777 의 배당금 지급은 수익으로 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 41.3% )로 1777 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YTW 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/03 23:11종가2026/08/03 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SYN-TECH Chem. & Pharm. Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yenya KuoCapital Securities CorporationXiaowei HuangMasterlink Securities Investment Advisory
Upcoming Dividend • Jul 09Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 16 July 2026. Payment date: 13 August 2026. Payout ratio is a comfortable 69% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (2.9%).
Declared Dividend • Jun 10Dividend reduced to NT$4.00Dividend of NT$4.00 is 25% lower than last year. Ex-date: 16th July 2026 Payment date: 13th August 2026 Dividend yield will be 5.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (69% earnings payout ratio) and cash flows (41% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 23% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.0% EPS decline seen over the last 5 years.
Upcoming Dividend • Jul 14Upcoming dividend of NT$5.30 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 15 August 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.6%).
Declared Dividend • Jun 11Dividend increased to NT$5.30Dividend of NT$5.30 is 51% higher than last year. Ex-date: 21st July 2025 Payment date: 15th August 2025 Dividend yield will be 6.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.9% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Upcoming Dividend • Jul 12Upcoming dividend of NT$3.50 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 57% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.0%).
Declared Dividend • Jun 22Dividend increased to NT$3.50Dividend of NT$3.50 is 17% higher than last year. Ex-date: 19th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (57% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 1.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Upcoming Dividend • Jul 09Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 16 July 2026. Payment date: 13 August 2026. Payout ratio is a comfortable 69% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (2.9%).
New Risk • Jun 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.16b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.16b market cap, or US$99.2m).
Declared Dividend • Jun 10Dividend reduced to NT$4.00Dividend of NT$4.00 is 25% lower than last year. Ex-date: 16th July 2026 Payment date: 13th August 2026 Dividend yield will be 5.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (69% earnings payout ratio) and cash flows (41% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 23% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.0% EPS decline seen over the last 5 years.
Reported Earnings • May 11First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.70 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00 (down from NT$1.70 in 1Q 2025). Revenue: NT$275.6m (down 13% from 1Q 2025). Net income: NT$71.7m (down 5.4% from 1Q 2025). Profit margin: 26% (up from 24% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
New Risk • Mar 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (91% payout ratio). Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.13b market cap, or US$99.1m).
Reported Earnings • Feb 28Full year 2025 earnings released: EPS: NT$5.87 (vs NT$8.82 in FY 2024)Full year 2025 results: EPS: NT$5.87 (down from NT$8.82 in FY 2024). Revenue: NT$1.30b (up 3.4% from FY 2024). Net income: NT$261.6m (down 34% from FY 2024). Profit margin: 20% (down from 31% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
공고 • Feb 24SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwan
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$1.73 (vs NT$2.60 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.73 (down from NT$2.60 in 3Q 2024). Revenue: NT$336.7m (up 1.9% from 3Q 2024). Net income: NT$77.4m (down 33% from 3Q 2024). Profit margin: 23% (down from 35% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Aug 07Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$2.21 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$2.21 in 2Q 2024). Revenue: NT$324.8m (down 5.3% from 2Q 2024). Net income: NT$16.6m (down 83% from 2Q 2024). Profit margin: 5.1% (down from 29% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year.
Upcoming Dividend • Jul 14Upcoming dividend of NT$5.30 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 15 August 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.6%).
Declared Dividend • Jun 11Dividend increased to NT$5.30Dividend of NT$5.30 is 51% higher than last year. Ex-date: 21st July 2025 Payment date: 15th August 2025 Dividend yield will be 6.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.9% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 09First quarter 2025 earnings released: EPS: NT$1.70 (vs NT$1.96 in 1Q 2024)First quarter 2025 results: EPS: NT$1.70 (down from NT$1.96 in 1Q 2024). Revenue: NT$315.8m (up 17% from 1Q 2024). Net income: NT$75.8m (down 13% from 1Q 2024). Profit margin: 24% (down from 32% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year and the company’s share price has also increased by 12% per year.
공고 • Apr 30SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2025 Results on May 07, 2025SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2025 results on May 07, 2025
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$83.00, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 38% over the past three years.
Reported Earnings • Mar 09Full year 2024 earnings released: EPS: NT$8.82 (vs NT$5.63 in FY 2023)Full year 2024 results: EPS: NT$8.82 (up from NT$5.63 in FY 2023). Revenue: NT$1.26b (up 13% from FY 2023). Net income: NT$393.3m (up 57% from FY 2023). Profit margin: 31% (up from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 16% per year.
공고 • Feb 25SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwan
공고 • Feb 15SYN-TECH Chem. & Pharm. Co., Ltd. to Report Fiscal Year 2024 Results on Feb 24, 2025SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report fiscal year 2024 results on Feb 24, 2025
New Risk • Nov 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • Nov 18Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: NT$330.6m (flat on 3Q 2023). Net income: NT$116.0m (up 26% from 3Q 2023). Profit margin: 35% (up from 28% in 3Q 2023).
공고 • Oct 26SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q3, 2024 Results on Nov 04, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q3, 2024 results on Nov 04, 2024
Reported Earnings • Aug 13Second quarter 2024 earnings released: EPS: NT$2.21 (vs NT$1.52 in 2Q 2023)Second quarter 2024 results: EPS: NT$2.21 (up from NT$1.52 in 2Q 2023). Revenue: NT$343.0m (up 40% from 2Q 2023). Net income: NT$98.6m (up 46% from 2Q 2023). Profit margin: 29% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.
공고 • Jul 27SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q2, 2024 Results on Aug 05, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q2, 2024 results on Aug 05, 2024
Upcoming Dividend • Jul 12Upcoming dividend of NT$3.50 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 57% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.0%).
Buy Or Sell Opportunity • Jul 08Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 18% to NT$98.20. The fair value is estimated to be NT$79.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.4% over the last 3 years. Earnings per share has grown by 3.9%.
Declared Dividend • Jun 22Dividend increased to NT$3.50Dividend of NT$3.50 is 17% higher than last year. Ex-date: 19th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (57% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 1.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$1.96 (vs NT$1.47 in 1Q 2023)First quarter 2024 results: EPS: NT$1.96 (up from NT$1.47 in 1Q 2023). Revenue: NT$269.8m (flat on 1Q 2023). Net income: NT$87.4m (up 33% from 1Q 2023). Profit margin: 32% (up from 25% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 2% per year.
공고 • Apr 28SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2024 Results on May 06, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2024 results on May 06, 2024
Buy Or Sell Opportunity • Apr 23Now 20% overvaluedOver the last 90 days, the stock has fallen 2.5% to NT$82.30. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 2.5%.
Buy Or Sell Opportunity • Mar 01Now 20% overvaluedOver the last 90 days, the stock has fallen 5.5% to NT$82.40. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 2.7%.
공고 • Feb 27SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024. Location: No.168, Kai Yuan Rd., Hsin-Ying District Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider 2023 Audit Committee's Review Report; to consider 2023 Employees and Directors' Compensation Information; to consider Status of 2023 Cash Dividend Distribution; to consider 2023 Directors' Remuneration Information; to consider 2023 Business Report and Financial Statements; to consider distribution plan of 2023 earnings; and to consider other matters.
Reported Earnings • Nov 08Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: NT$2.07 (down from NT$2.54 in 3Q 2022). Revenue: NT$330.4m (up 17% from 3Q 2022). Net income: NT$92.5m (down 18% from 3Q 2022). Profit margin: 28% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Aug 08Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: EPS: NT$1.51 (down from NT$3.11 in 2Q 2022). Revenue: NT$245.1m (down 17% from 2Q 2022). Net income: NT$67.5m (down 46% from 2Q 2022). Profit margin: 28% (down from 42% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) exceeded analyst estimates by 18%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.
Upcoming Dividend • Jul 14Upcoming dividend of NT$3.00 per share at 3.5% yieldEligible shareholders must have bought the stock before 21 July 2023. Payment date: 18 August 2023. Payout ratio is a comfortable 44% but the company is not cash flow positive. Trailing yield: 3.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (1.7%).
Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: NT$6.62 (up from NT$3.38 in FY 2021). Revenue: NT$986.3m (up 32% from FY 2021). Net income: NT$295.3m (up 184% from FY 2021). Profit margin: 30% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) missed analyst estimates by 4.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
공고 • Dec 30SYN-TECH Chem. & Pharm. Co., Ltd. Announces Appointment of Corporate Governance OfficerSYN-TECH Chem. & Pharm. Co., Ltd. announced appointment of Corporate Governance Officer. Name, title, and resume of the previous position holder: N/A. Name, title, and resume of the new position holder: Maggie Juang /financial & accounting officer of Syn-Tech. Effective date: December 29, 2022.
Price Target Changed • Nov 16Price target decreased to NT$80.00Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$76.40. Stock is up 9.1% over the past year. The company is forecast to post earnings per share of NT$3.02 for next year compared to NT$3.38 last year.
Reported Earnings • Nov 06Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: NT$2.54 (up from NT$0.94 in 3Q 2021). Revenue: NT$281.8m (up 77% from 3Q 2021). Net income: NT$113.3m (up 302% from 3Q 2021). Profit margin: 40% (up from 18% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 37%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 07Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: NT$1.72 (up from NT$0.74 in 2Q 2021). Revenue: NT$209.1m (down 3.3% from 2Q 2021). Net income: NT$68.8m (up 209% from 2Q 2021). Profit margin: 33% (up from 10% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 192%. Over the next year, revenue is forecast to grow 32%, compared to a 39% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
공고 • Aug 03SYN-TECH Chem. & Pharm. Co., Ltd. Announces Executive ChangesSYN-TECH Chem. & Pharm. Co., Ltd. announced that Chun-Cheng, Hung/synthesis department manager of SCP, has replaced Chun-Tzer, Tsai/director of Syn-Tech, as Research and development officer. Syn-Tech has announced the change of research and development officer on July 1, 2022. The case was approved by the board of Syn-Tech on August 1, 2022.
Upcoming Dividend • Jul 14Upcoming dividend of NT$1.93 per shareEligible shareholders must have bought the stock before 21 July 2022. Payment date: 19 August 2022. Payout ratio is a comfortable 75% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (6.8%). In line with average of industry peers (2.8%).
공고 • Jul 03SYN-TECH Chem. & Pharm. Co., Ltd. Announces Change of Research and Development OfficerSYN-TECH Chem. & Pharm. Co., Ltd. announced change of research and development officer. Name, title, and resume of the previous position holder: Chun-Tzer, Tsai/director of Syn-Tech. Name, title, and resume of the new position holder: Chun-Cheng, Hung/synthesis department manager of SCP. Effective date is July 1, 2022.
공고 • Jun 22SYN-TECH Chem. & Pharm. Co., Ltd. Announces Cash Dividend, Payable on August 19, 2022SYN-TECH Chem. & Pharm. Co., Ltd. announced cash dividend of TWD 86,128,033 (TWD 2.15 per share). Ex-rights (Ex-dividend) date is July 21, 2022. Ex-rights (Ex-dividend) record date is July 27, 2022. Payment date of cash dividend distribution is August 19, 2022.
Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: NT$0.85 (down from NT$1.73 in 1Q 2021). Revenue: NT$159.5m (down 32% from 1Q 2021). Net income: NT$34.2m (down 34% from 1Q 2021). Profit margin: 22% (in line with 1Q 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 73%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Price Target Changed • Apr 27Price target decreased to NT$66.00Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$65.30. Stock is down 35% over the past year. The company is forecast to post earnings per share of NT$2.47 for next year compared to NT$3.38 last year.
Reported Earnings • Mar 12Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: NT$3.38 (down from NT$6.21 in FY 2020). Revenue: NT$746.6m (down 24% from FY 2020). Net income: NT$103.8m (down 44% from FY 2020). Profit margin: 14% (down from 19% in FY 2020). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Over the next year, revenue is expected to shrink by 9.3% compared to a 20% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 5% per year.
Reported Earnings • Nov 10Third quarter 2021 earnings released: EPS NT$0.94 (vs NT$1.14 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: NT$159.2m (down 28% from 3Q 2020). Net income: NT$28.2m (down 18% from 3Q 2020). Profit margin: 18% (up from 16% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 09Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 16 September 2021. Payment date: 07 October 2021. Trailing yield: 5.5%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.3%).
Reported Earnings • Aug 06Second quarter 2021 earnings released: EPS NT$0.74 (vs NT$2.35 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$216.3m (down 29% from 2Q 2020). Net income: NT$22.2m (down 69% from 2Q 2020). Profit margin: 10% (down from 23% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • May 06First quarter 2021 earnings released: EPS NT$1.73 (vs NT$1.56 in 1Q 2020)The company reported a solid first quarter result with improved earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: NT$235.6m (flat on 1Q 2020). Net income: NT$52.0m (up 11% from 1Q 2020). Profit margin: 22% (up from 20% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to NT$95.60, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 35% over the past three years.
분석 기사 • Mar 19SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공고 • Mar 18SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million.SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million on March 16, 2021. The transaction will be settled by exchange of 4.5 million shares of SYN-TECH of NTD 75.24 per share. If there is insufficient exchange for one share, SYN-TECH shall, within 30 days after completing amendment registration, pay the difference between assessed business value and the share value in cash to SCP at once. The deal is subject to Standard Chemical obtaining approval from shareholders and is expected to close on October 1, 2021.
Reported Earnings • Mar 18Full year 2020 earnings released: EPS NT$6.21 (vs NT$5.31 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$983.8m (up 3.9% from FY 2019). Net income: NT$186.7m (up 17% from FY 2019). Profit margin: 19% (up from 17% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
공고 • Mar 17SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021, at 14:00 Taipei Standard Time. Location: No.168, Kai Yuan Rd., Hsin-Ying District, Tainan City Taiwan Agenda: To consider 2020 Business Report; to consider Supervisors' Review Report on 2020 Financial Statements; to consider 2020 Employees' Compensation and Directors & Supervisors' Compensation Information; to consider Syn-Tech will transfer the API synthesis department that spinning-off from S.C.P, and issue new shares; to consider 2020 Business Report and Financial Statements; to consider the proposed distribution plan for year 2020 earnings; to consider the amendment to the Articles of Incorporation; to consider the amendment to the Procedures for Election of Directors and Supervisors; to consider the amendment to the Regulations Governing the Acquisition and Disposal of Assets; to consider the amendment to the Regulations Governing Loaning of Funds; and to consider other matters.
Is New 90 Day High Low • Feb 27New 90-day high: NT$82.50The company is up 9.0% from its price of NT$75.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period.
분석 기사 • Feb 26Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend YieldIs SYN-TECH Chem. & Pharm. Co., Ltd. ( GTSM:1777 ) a good dividend stock? How can we tell? Dividend paying companies...
분석 기사 • Feb 05Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?SYN-TECH Chem. & Pharm (GTSM:1777) has had a rough month with its share price down 1.2%. However, stock prices are...
분석 기사 • Jan 10SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their SharesIdeally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...
Is New 90 Day High Low • Dec 21New 90-day high: NT$77.30The company is up 2.0% from its price of NT$75.50 on 23 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period.
분석 기사 • Dec 19SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather SparinglySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Nov 28Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend YieldIs SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) a good dividend stock? How can we tell? Dividend paying companies...
Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS NT$1.14The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$220.3m (down 20% from 3Q 2019). Net income: NT$34.3m (down 39% from 3Q 2019). Profit margin: 16% (down from 21% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 13New 90-day low: NT$73.70The company is down 16% from its price of NT$88.00 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: NT$75.60The company is down 16% from its price of NT$89.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.